Table 2.
Detailed information of irAEs of included studies.
| Author | Sum AID | Any irAEs (%) | ≥G3 irAEs (%) | Sum non-AID | Any irAEs (%) | ≥G3 irAEs (%) |
|---|---|---|---|---|---|---|
| Danlos et al.25 | 45 | 20 (44.4%) | NA | 352 | 84 (23.9%) | NA |
| Kanai et al.24 | 26 | 8 (31%) | 5 (19%) | 190 | 22 (12%) | 10 (5%) |
| Schadendorf et al.26 | 25 | 25 (100%) | 14 (56%) | 983 | 948 (96.4%) | 446 (45.4%) |
| Cortellini et al.22 | 85 | 56 (65.9%) | 8 (9.4%) | 666 | 266 (39.9%) | 59 (8.8%) |
| Shibaki et al.20 | 14 | 4 (29%) | 1 (7.1%) | 196 | 22 (11%) | 8 (4.1%) |
| Tasaka et al.21 | 49 | 15 (30.6%) | NA | 412 | 39 (9.5%) | NA |
| Loriot et al.23 | 35 | 24 (69%) | 9(26%) | 962 | 506 (53%) | 112 (12%) |
| bVan der Kooij et al.27 | 187 | NA | 31 (16.6%) | 1540 | NA | 206 (13.4%) |
aWe chose the patients treated with anti-PD-1 because they are the most in this study; AID: autoimmune disease; irAEs: immune-related adverse events; G3: grade 3; NA: not available.